The Efficacy of Cimetropium Bromide as a Premedication before Esophagogastroduodenoscopy.
- Author:
Jue Yong LEE
1
;
Sung Jung KIM
;
Chang Soon CHOI
;
Young Mook KIM
;
Hyun Joo JEONG
;
Jung Eun LEE
;
Gwang Ho BAIK
;
Jin Bong KIM
;
Dong Joon KIM
Author Information
1. Department of Internal Medicine, Hallym University College of Medicine, Chuncheon, Korea. ksjungdr@hallym.or.kr
- Publication Type:Randomized Controlled Trial ; Original Article
- Keywords:
Antispasmodics;
Cimetropium bromide;
Esophagogastroduodenoscopy;
Premedication
- MeSH:
Endoscopy, Digestive System;
Humans;
Injections, Intramuscular;
Outpatients;
Parasympatholytics;
Premedication;
Scopolamine Derivatives;
Surveys and Questionnaires
- From:Korean Journal of Gastrointestinal Endoscopy
2008;37(6):403-408
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND/AIMS: Cimetropium bromide has been used widely as a premedication for endoscopy; however, there are no subjective data pertaining to the effects of cimetropum bromide as a premedication. Thus, the current study was undertaken to compare the effects of cimetropum bromide with placebo as a premedication for esophagogastroduodenoscopy (EGD). METHODS: Two hundred ninety-nine consecutive outpatients who had undergone EGD were enrolled in this study. Thirty minutes before EGD, the patients were randomly given an intramuscular injection of cimetropium bromide (5 mg) or saline using a placebo-controlled, double-blind, randomized technique. Immediately after EGD, all the patients and endoscopists were requested to fill out the questionnaire form. RESULTS: One-hundred patients were injected with cimetropium bromide and 150 patients were injected with placebo. There was no statistically significant difference in the degree of residual gastric secretions, the peristaltic activity detected by endoscopists, and the comfort experienced by the patients in each study group. CONCLUSIONS: The intramuscular injection of cimetropium bromide (5 mg) as a premedication for EGD was not significantly superior to placebo, at least with respect to subjective parameters, in spite of its broad use.
